Bellus Health
Bellus Health was a Canadian clinical-stage biotech developing camlipixant, a selective P2X3 antagonist for refractory chronic cough, that was acquired by GSK in April 2023 for $2 billion before reaching commercialization.
- Company typePrivate
- Founded1993
- HeadquartersLaval, Canada
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Bellus Health does
BELLUS Health Inc. was a Canadian clinical-stage biotechnology company headquartered in Laval, Quebec, that developed therapeutics for rare and specialty diseases, with its strategic focus on camlipixant — a selective P2X3 receptor antagonist designed to treat refractory chronic cough by targeting the underlying mechanism of cough reflex hypersensitization. The company was founded in 1993 and built its clinical value around a single late-stage asset, advancing camlipixant through Phase III development: the CALM-1 trial was completed, and CALM-2 enrollment was finished after the sample size was expanded and patient-reported outcome endpoints were added to strengthen the regulatory package. The compound targeted a significant unmet medical need, with an addressable population estimated at approximately 12.9 million chronic cough cases in the US, a comparable cohort in the EU4 and UK, and 930,000 diagnosed cases in Japan.
The business model was that of a pre-commercial biotech: Bellus Health generated no product revenue and relied on capital markets to fund R&D, executing a $200 million public offering of common shares in December 2021 and multiple prior private and public financings totaling several hundred million dollars. The company pursued traditional biotech go-to-market motions — scientific communication through medical conferences, peer-reviewed publications, and investor relations — with no commercial sales infrastructure because camlipixant had not yet received regulatory approval. Customers in the eventual commercial sense would be refractory chronic cough patients and the payers/providers serving them, but Bellus Health had no direct customer relationships at the time of acquisition. In April 2023, GSK plc acquired Bellus Health for $2 billion, integrating camlipixant into GSK's respiratory, immunology and inflammation R&D division, and Bellus Health ceased operating as an independent company.
Bellus Health firmographics
Firmographics- Name
- Bellus Health
- Legal name
- BELLUS Health Inc.
- Website
- https://bellushealth.com
- Company type
- Private
- Founded year
- 1993
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- Bellus Health was a Canadian clinical-stage biotech developing camlipixant, a selective P2X3 antagonist for refractory chronic cough, that was acquired by GSK in April 2023 for $2 billion before reaching commercialization.
- Ownership category
- akta.pro rank
Bellus Health industry classification
Industry- Product category
- Clinical-stage biopharmaceutical / respiratory therapeutics
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)
- akta.pro secondary industries
- CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)
Keywords
Where Bellus Health is headquartered
LocationHeadquarters
- HQ city
- Laval
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Bellus Health business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Public Equity Offering: Bellus Health raised $200 million through a public offering of common shares in Canada and the US. The offering involved 25 million shares at $8.00 each with an option for additional shares.
- Acquisition Proceeds: Bellus Health was acquired by GSK plc in April 2023 for $2 billion to expand its respiratory portfolio with the investigational chronic cough treatment camlipixant.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Bellus Health product offering
Product offeringCore offering
Bellus Health was a clinical-stage biopharmaceutical company developing camlipixant, a selective P2X3 antagonist intended as a targeted therapy for refractory chronic cough. As a pre-commercial firm, it did not sell any approved products; its core activity was running Phase III clinical trials (CALM-1 and CALM-2) in pursuit of regulatory approval, with the asset ultimately acquired by GSK in April 2023 for $2 billion.
Product overview
Bellus Health was a Canadian biotech company focused on developing innovative medicines for respiratory diseases. Its primary product was camlipixant, a selective P2X3 antagonist that completed Phase III trials for refractory chronic cough treatment. The company was acquired by GSK in 2023 for approximately $2 billion.
Differentiator
Problem solved
Functional benefit
Products and services
- Camlipixant
Quantifiable outcome
- Estimated 12.9 million chronic cough cases in the US, 8.2 million females vs 5.9 million males in EU4 and UK, and 930,000 diagnosed cases in Japan
Companies that use Bellus Health
Customer profileSegments1 record
Ideal customer profiles1 record
Bellus Health technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Bellus Health partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- GSK plcflagshipIn April 2023, UK-based GSK plc acquired Canadian biotech firm Bellus Health for $2 billion to expand its respiratory portfolio with the investigational chronic cough treatment camlipixant. The acquisition gave GSK access to Bellus Health's selective P2X3 antagonist in Phase III trials for refractory chronic cough treatment. GSK integrated Bellus Health's assets into its respiratory, immunology and inflammation R&D division.
Scale indicators3 records
Recent moves6 records
Expansion highlights4 records
Bellus Health competitors and assessment
Company assessmentDirect peers
- Merck & Co. Developed gefapixant, a direct P2X3 antagonist competitor to camlipixant for refractory chronic cough, making it the most closely comparable clinical-stage rival in the same mechanism class.
- Shionogi: Developed sivopixant, a selective P2X3 antagonist approved in Japan for refractory chronic cough, directly competing with camlipixant in the same target indication and mechanism.
- Bayer: Advanced eliapixant, a P2X3 antagonist for refractory chronic cough, placing Bayer as a direct mechanism competitor with overlapping development pathway.
Emerging players
- NeRRe Therapeutics: Clinical-stage company developing neurokinin-1 receptor antagonists (e.g., orvepitant) for chronic cough, addressing the same refractory cough patient population via a different but adjacent mechanism.
- Algernon Pharmaceuticals: Small-cap biotech investigating ifenprodil and other candidates for chronic cough, representing an emerging player pursuing alternative mechanisms in the same disease space.
- Patara Pharma: Clinical-stage company focused on refractory chronic cough therapeutics (e.g., PA101 / cromolyn), addressing the same patient population with a different delivery/format approach.
Broad incumbents
- GSK plc: Acquirer of Bellus Health; a global respiratory incumbent integrating camlipixant into its specialty respiratory franchise and the only player that combines Bellus's asset with established commercial reach.
- AstraZeneca: Global respiratory pharma with a deep specialty franchise (e.g., Fasenra, Trixeo) competing for refractory cough prescribing and representing the broader incumbent benchmark for camlipixant's commercial potential.
- Boehringer Ingelheim: Major respiratory and immunology incumbent (Spiriva, Ofev) with capabilities overlapping camlipixant's target prescriber base and a logical competitive reference for the refractory cough opportunity.
- Novartis: Diversified respiratory player (e.g., Xolair, Ultibro) with global commercial reach into the same specialist pulmonology and allergy channels relevant to camlipixant's future launch.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Bellus Health social profiles
Digital presenceBellus Health financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bellus Health leadership team
Management profileNumber of profiles
Profiles7 records
Bellus Health funding detail
Funding detailFunding overview
Funding rounds7 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bellus Health M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bellus Health
What does Bellus Health do?
Bellus Health was a clinical-stage biopharmaceutical company developing camlipixant, a selective P2X3 antagonist intended as a targeted therapy for refractory chronic cough. As a pre-commercial firm, it did not sell any approved products; its core activity was running Phase III clinical trials (CALM-1 and CALM-2) in pursuit of regulatory approval, with the asset ultimately acquired by GSK in April 2023 for $2 billion.
Is Bellus Health a public or private company?
Bellus Health is a private company. It is classified as corporate owned and is currently acquired.
When was Bellus Health founded?
Bellus Health was founded in 1993. It employs 51 to 100 people.
Where is Bellus Health based?
Bellus Health is headquartered in Laval, Canada, in the North America region.
How does Bellus Health make money?
Two revenue lines are on record. Public Equity Offering is the primary driver. The others are acquisition Proceeds.
Who are Bellus Health's main competitors?
Direct peers on record are Merck & Co., Shionogi and Bayer. Emerging players are NeRRe Therapeutics, Algernon Pharmaceuticals and Patara Pharma. Broad incumbents are GSK plc, AstraZeneca, Boehringer Ingelheim and Novartis.
Does Bellus Health have an API?
No public API is recorded for Bellus Health.
What industry is Bellus Health in?
Bellus Health's product category is Clinical-stage biopharmaceutical / respiratory therapeutics. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution), with a secondary code of HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development). Its NAICS code is 5417 and its SIC code is 2836.